In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...
CD19 still remains the strongest contender in CAR-T cell therapy. According to ClinicalTrials.gov, over 600 CAR T cell clinical trials have been carried out to date, a majority of which aiming to ...
A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.
Chimeric antigen receptor T cell therapy (CAR-T cell therapy) is a new kind of immunotherapy with encouraging results in the treatment of hematological malignancies. At present, CD19 is the most ...
A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...
B-cell depletion with unconjugated CD20 monoclonal antibody (mAb) is used to treat rheumatoid arthritis and other autoimmune diseases. CD20-targeted immunotherapy depletes mature B cells through ...
Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial We conducted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback